Covid-19 roundup: BioN­Tech go­ing head-to-head with Mod­er­na as PhI­II mR­NA launch looms; Tri­al on Shin­zo Abe’s once-fa­vorite an­tivi­ral is in­con­clu­sive

It’s a race to the Phase III fin­ish line now for the 2 lead­ing mR­NA vac­cines in the pipeline for Covid-19.

BioN­Tech chief Ugur Sahin told the Wall Street Jour­nal that his com­pa­ny will start Phase III test­ing of their vac­cine lat­er this month, set­ting them up to lat­er­al the da­ta to reg­u­la­tors be­fore the end of this year.

That puts them es­sen­tial­ly on the ex­act same sched­ule as Mod­er­na is ded­i­cat­ed to. The Mass­a­chu­setts ri­val to BioN­Tech al­so ex­pects to launch Phase III this month. Lots of ru­mors have cir­cu­lat­ed about de­lays and con­flict among the sci­en­tists ad­vanc­ing the Mod­er­na jab, but the biotech has con­sis­tent­ly stuck to its plan to start a late-stage piv­otal this month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.